Medindia

X

Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma

Thursday, June 2, 2011 General News J E 4
Advertisement
Clinical Study Seeks to Evaluate MORAb-004 as a Single Agent for Extending Progression-Free Survival of Patients with Metastatic Disease

Contacts:  

Media Inquiries

Investor Inquiries

Terry Cushmore

Rod Dausch

Morphotek, Inc.

Morphotek, Inc.

610-423-6197

610-423-6111

tcushmore@morphotek.com

Dausch@morphotek.com

Media Inquiries

Investor Inquiries

Lynn Kenney

Alex Scott

Eisai Inc.

Eisai Inc.

201-746-2294

201-746-2177

lynn_kenney@eisai.com

alex_scott@eisai.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Kendle Appoints Robert Shepard, MD, FACP Executive...
S
Hospice Foundation of America Webinar To Focus on ...